

Edgar Filing: NOVAVAX INC - Form 8-K

NOVAVAX INC
Form 8-K
March 12, 2001

1

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT UNDER SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): March 12, 2001

NOVAVAX, INC.

(Exact name of registrant as specified in its charter)

DELAWARE ----- (State or other jurisdiction of incorporation or organization)	0-26770 ----- (Commission File No.)	22-2816046 ----- (I.R.S. Employer Identification No.)
--	--	--

8320 GUILFORD ROAD, COLUMBIA, MD ----- (Address of principal executive offices)	21046 ----- (Zip code)
---	------------------------------

(301) 854-3900

Registrant's telephone number, including area code

NOT APPLICABLE

(Former name or former address, if changed since last report)

2

NOVAVAX, INC.
ITEMS TO BE INCLUDED IN THIS REPORT

ITEM 7. EXHIBITS.

- (c) Exhibits.
99.1 Press Release of Novavax, Inc. dated March 12, 2001.

ITEM 9. REGULATION FD DISCLOSURE.

In the year end financial results press release, Novavax projected revenues to exceed \$20 million in 2001.

A copy of the press release relating to the event in Item 9 above, was issued on March 12, 2001 and is attached as Exhibit 99.1 and incorporated herein by this reference.

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NOVAVAX, INC.

Date: March 12, 2001

By: /s/ DENNIS W. GENGE

Dennis W. Genge, Vice President
And Chief Financial Officer/Treasurer